Tezepelumab significantly reduced asthma exacerbations: Phase 3 NAVIGATOR trial
Pregnancy during COVID-19 lockdown: How the pandemic has affected new mothers
19 May 2021Is it normal aging or early signs of dementia?
19 May 2021Tezepelumab significantly reduced asthma exacerbations: Phase 3 NAVIGATOR trial
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference. NAVIGATOR (NCT03347279) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial.
